Allergan plc (AGN)
Healthcare | Drugs - Generic
CEO: Brenton L. Saunders
Allergan plc receives a in our proprietary ranking system that combines valuation, moat, operational performance, and financial strength. View the Top 50 tickrz ranked stocks here.
Valuation is the most heavily weighted component in our tickrz ranking methodology. Numerous academic and practitioner studies have found that a value approach outperforms the market over the long-run. Allergan plc 's valuation score is comprised of a P/E ratio of 6.2x, a P/B ratio of 1.1x, a P/S ratio of 5x, and an EV/EBITDA ratio of 39.4x. .
WARREN BUFFETT RANKING
Allergan plc ranks 42 out of the S&P 500 constituents in our multi-factor Warren Buffett ranking methodology. This is a strong score, meaning it ranks highly on valuation, moat, volatility, and financial strength factors.
To calculate a company's Moat Score, we look at its historical earnings growth, historical average return on equity, the volatility of its earnings stream, and also factor in the strength of its balance sheet. Allergan plc appears to have a durable competitive advantage within the Healthcare sector.
Allergan plc has a Piotroski F Score of 7 out of 9. The F Score examines changes in profitability, leverage, liquidity, and operating efficiency. Interest coverage of -3.4x, a debt/equity ratio of 42% and a Moat Rank of 139 translate to an average Financial Strength score.
Investment research has shown that stocks with strong performance over the last 6 to 12 months tend to perform better in the medium term than stocks with poor performance over the same period. In fact, the momentum factor is one of the strongest of all the investment factors. The company has seen its stock appreciate by 4.17% over the last 12 months. This performance is weak compared to other stocks in the S&P 500, earning it a rank of 355.
VALUE + YIELD
Unfortunately we do not have enough data to provide a dividend ranking for Allergan plc .
A company's growth metrics are less important than its valuation, moat, and financial strength. However, a check on growth can be a good way to avoid companies in secular decline. Its 79.3% 5 year annualized EPS growth, 26% 5 year annualized sales-per-share growth, and 5 year annualized book value-per-share growth of 50% speak to its impressive growth ranking.